Lördag 21 December | 17:16:26 Europe / Stockholm

Svenska | English

Brain+

Kalender

	Tid*
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-16	-	X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15	-	Årsstämma
2024-05-07	-	Bokslutskommuniké 2023
2023-10-11	-	Extra Bolagsstämma 2023
2023-08-31	-	Kvartalsrapport 2023-Q2
2023-05-30	-	X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26	-	Årsstämma
2023-04-28	-	Bokslutskommuniké 2022
2022-09-29	-	Kvartalsrapport 2022-Q2
2022-09-02	-	Extra Bolagsstämma 2022
2022-05-19	-	X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18	-	Årsstämma
2022-04-29	-	Bokslutskommuniké 2021

Beskrivning

Land	Danmark
Lista	First North Denmark
Sektor	Hälsovård
Industri	Vård & Omsorg

Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.

Filter

År

Typ

Språk

Rensa

2024-12-10 08:45:34 Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status 0,10 DKK | -0,62% | 0,00 MDKK

2024-12-05 08:51:54 Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality 0,10 DKK | +7,02% | 0,06 MDKK

2024-11-21 15:30:00 Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities 0,09 DKK | 0,00% | 0,00 MDKK

2024-11-01 11:57:51 Brain+ closes new Danish municipality sales contract on Ayla – your CST Assistant 0,10 DKK | -4,21% | 0,04 MDKK

2024-10-21 11:54:20 Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy 0,10 DKK | +0,50% | 0,02 MDKK

2024-10-11 09:04:32 Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions 0,09 DKK | 0,00% | 0,01 MDKK

2024-10-07 11:50:50 Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue 0,08 DKK | 0,00% | 0,02 MDKK

2024-10-02 10:32:09 Brain+ launches Ayla – your CST Assistant into the UK dementia market 0,08 DKK | +9,33% | 0,04 MDKK

2024-10-01 12:11:29 Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions 0,07 DKK | -9,42% | 0,04 MDKK

2024-10-01 09:23:35 Ayla – your CST Assistant has been registered in the UK as a certified Medical Device Software for dementia therapy 0,07 DKK | -9,42% | 0,04 MDKK

2024-09-25 10:43:43 Brain+ confirms imminent commercial launch of Ayla – your CST Assistant as a medical device in the UK 0,08 DKK | 0,00% | 0,08 MDKK

2024-09-23 12:15:34 Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization 0,07 DKK | -6,27% | 0,09 MDKK

2024-09-20 08:43:33 Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4% 0,08 DKK | -2,68% | 0,06 MDKK

2024-09-17 10:46:49 Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4 0,08 DKK | +0,98% | 0,07 MDKK

2024-09-13 10:33:42 Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027 0,09 DKK | 0,00% | 0,01 MDKK

2024-09-13 09:08:14 Brain+ A/S announces the exercise price for its warrants of series TO 4 0,09 DKK | 0,00% | 0,01 MDKK

2024-09-05 09:30:00 First patient enrolled in a clinical trial to evaluate Brain+’ next generation cognitive training technology for Mild Cognitive Impairment 0,10 DKK | -0,21% | 0,06 MDKK

2024-09-03 08:30:00 Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit 0,10 DKK | -0,83% | 0,01 MDKK

2024-08-30 12:35:56 Invitation to Investor Webinar on Tues 3 Sept 2024 at 16:00 CEST: H1 2024 report and new Chief Commercial Officer 0,10 DKK | -0,60% | 0,06 MDKK

2024-08-29 19:08:00 H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected 0,10 DKK | -0,60% | 0,06 MDKK

2024-08-27 12:30:00 The CER of the CST-Assistant validated for UK regulatory compliance, documenting the product’s clinical performance 0,10 DKK | +15,93% | 0,15 MDKK

2024-08-23 08:50:00 Brain+ fully on track towards market entry and first sales in the United Kingdom in H2 2024 0,08 DKK | +4,50% | 0,06 MDKK

2024-07-12 10:31:22 New UK Labour government will focus on healthtech and dementia treatment as part of UK healthcare reform 0,11 DKK | +19,02% | 0,37 MDKK

2024-07-09 10:18:03 The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark 0,13 DKK | +8,61% | 0,02 MDKK

2024-07-05 13:34:54 Directed issue of units to guarantors and registration of shares from both the rights issue and the directed issue 0,15 DKK | +13,08% | 0,12 MDKK

2024-06-28 10:00:00 Brain+ hires UK health tech rising star as Chief Commercial Officer 0,12 DKK | -32,07% | 0,33 MDKK

2024-06-27 10:08:17 Brain+ A/S publishes the outcome of its rights issue of units 0,18 DKK | +18,71% | 0,20 MDKK

2024-06-24 10:06:20 Brain+ obtains additional guarantee commitment in its ongoing rights issue 0,10 DKK | +20,19% | 0,25 MDKK

2024-06-21 08:45:00 Last day for subscription in the ongoing rights issue 0,08 DKK | +11,38% | 0,02 MDKK

2024-06-20 13:50:42 Correction - Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue 0,07 DKK | -3,40% | 0,02 MDKK

2024-06-20 12:37:15 Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue 0,07 DKK | -3,40% | 0,02 MDKK

2024-06-17 09:33:37 Brain+ establishes UK subsidiary 0,06 DKK | -14,29% | 0,03 MDKK

2024-06-14 12:23:37 The CST-Assistant v2.0 is now ready for release in Denmark and on track for release in the UK end of Q3 2024 0,07 DKK | -6,42% | 0,06 MDKK

2024-06-11 08:47:10 The subscription period in Brain+ unit rights issue begins today 0,08 DKK | +0,50% | 0,12 MDKK

2024-06-04 08:30:00 Brain+ A/S informs of the last day of trading in its shares including preferential rights to subscribe in the upcoming unit rights issue 0,08 DKK | -4,25% | 0,06 MDKK

2024-06-03 11:51:10 First steps taken to integrate CST-Assistant training with the formal CST-education in DK – a key market gateway milestone, also paving way for the UK 0,09 DKK | +2,39% | 0,02 MDKK

2024-05-31 13:59:28 Brain+ A/S: Publication of investment brochure 0,09 DKK | +3,37% | 0,03 MDKK

2024-05-24 09:33:00 Brain+’ invites to online investor event with new Chairman 0,09 DKK | +0,85% | 0,02 MDKK

2024-05-22 11:17:52 Minutes of Annual General Meeting in Brain+ 0,09 DKK | -7,01% | 0,03 MDKK

2024-05-16 11:02:56 Brain+ informs of progress on its UK focused proof-of-business strategy plan 0,09 DKK | -2,44% | 0,03 MDKK

2024-05-07 22:16:14 Brain+ A/S convenes the Annual General Meeting 0,09 DKK | -11,85% | 0,02 MDKK

2024-05-07 13:03:00 Brain+ publishes its Annual Report for 2023 – A year of market access, product development and a refocused commercial strategy 0,10 DKK | -17,25% | 0,06 MDKK

2024-05-07 08:52:31 Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan 0,10 DKK | -17,25% | 0,06 MDKK

2024-05-02 08:30:00 Brain+ updates on implementation and scaling activities for its CST-Assistant in Denmark 0,11 DKK | -8,08% | 0,01 MDKK

2024-04-30 13:48:00 Brain+’ CST-Assistant cited in leading Nordic Life Science magazine as an impactful health tech intervention for managing dementia 0,12 DKK | +5,24% | 0,01 MDKK

2024-04-30 11:51:00 Brain+ releases preliminary annual financial statements for 2023 0,12 DKK | +5,24% | 0,01 MDKK

2024-04-29 09:45:00 Brain+ announces a change in its Financial Calendar for 2024 0,12 DKK | -4,25% | 0,06 MDKK

2024-04-26 08:49:00 Successful educational CST course held with Malteser Germany based on the CST-Assistant 0,12 DKK | +1,57% | 0,01 MDKK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Brain+

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden